Devil's claw Harpagophytum procumbens (Burch.) DC.
Also called: Harpagophytum, grapple plant, wood spider, Uncaria procumbens Burch. (synonym)
Devil's claw is a southern African plant whose dried tuberous roots are used in extracts, powders and teas. Most of the world's supply comes from Namibia, with lesser amounts from South Africa and Botswana.
- Category
- Botanical
- Part used
- Dried tuberous roots
- Strongest evidence
- B Some positive trials
- Native range
- Native to southern Africa (POWO: "S. Africa"; WCVP distribution: Botswana, Namibia, Zimbabwe, Eswatini, Lesotho and South African provinces)
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2004 systematic review (BMC Complement Altern Med) described, without pooling, 12 trials of oral Harpagophytum preparations alone; 11 are described as randomized (five hip or knee osteoarthritis, 385 patients; four low back pain, 505 patients; two mixed pain), though one is titled a cohort study. [3]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBones and joints3 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Non-specific low back pain in adults | B | A Cochrane review found that daily extracts standardized to 50 mg or 100 mg harpagoside may beat placebo for short-term pain and rescue-medication use (two trials, 315 participants, low-quality evidence). [2] |
| Knee and hip osteoarthritis | C | In a 4-month double-blind trial of 122 patients, powdered root was comparable to diacerhein 100 mg/day for pain and function, with less diarrhea; there was no placebo group. [4] |
| Osteoarthritis and back pain (systematic review) | C | A 2004 review of 12 trials could not pool data; it rated evidence limited for low-harpagoside ethanolic extracts and moderate for powder at 60 mg harpagoside in osteoarthritis. [3] |
Main constituents: Iridoid glycoside harpagoside in root extracts [8]; Harpagide (an iridoid glycoside) and beta-sitosterol [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Extracts standardized to 50 mg or 100 mg harpagoside daily (low back pain trials). [2]
- Six capsules a day, each with 435 mg of cryoground root powder, for 4 months (osteoarthritis trial). [4]
- EU monograph (2016), adults: for minor joint pain, e.g. 4.5 g of root as a tea divided into 3 doses daily; consult a doctor if symptoms last over 4 weeks. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingSafety during pregnancy and lactation has not been established …
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 or 3A4; P-glycoprotein substrates
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (HMPC, traditional use, EMA/HMPC/627057/2015 adopted 12 July 2016), adults and elderly, minor joint pain: e.g.
Details and sources
- Not to be used with an active stomach or duodenal ulcer; people with gallstones should consult a physician first (EU monograph). [5]
- A case-control study suggests increased risk of acute pancreatitis; ulcers and gastrointestinal bleeding, raised blood pressure (one case) and a bowel obstruction from a herbal bezoar (one case) have been reported. [1]
- A safety review of 28 clinical trials found minor adverse events, mainly gastrointestinal, in about 3% of patients, and no higher rate than placebo in double-blind studies. [6]
- Reported side effects also include headache, vertigo and allergic reactions (rash, hives, facial swelling). [5]
- Pregnancy and breastfeeding: safety not established and use not recommended; not recommended under 18 years. [5]
Interactions
| With | What happens |
|---|---|
| Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 or 3A4 | MSK states devil's claw root can inhibit these enzymes and may interact with drugs they metabolize, but conflicting data suggest the interactions are not clinically relevant. [1] |
| P-glycoprotein substrates | Devil's claw modulates both the activity and expression of P-glycoprotein and may affect transport of drugs it carries; clinical significance is not known. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
Regulatory status
- EU: European Union herbal monograph (HMPC, traditional use; EMA/HMPC/627057/2015, adopted 12 July 2016 after the first systematic review) for relief of minor articular pain, and of mild digestive disorders such as bloating and flatulence where there is temporary loss of appetite. [5]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; manufacturers and distributors have initial responsibility for their safety. [7]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming devil's claw (Harpagophytum) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Drugs metabolized by CYP1A2, 2C8, 2C9, 2C19, 2D6 or 3A4: MSK states devil's claw root can inhibit these enzymes and may interact with drugs they metabolize; conflicting data suggest the interactions are not clinically relevant. [P2]
- P-glycoprotein substrates: Devil's claw modulates both the activity and expression of P-glycoprotein and may affect transport of drugs it carries; clinical significance not known. [P2]
- Medicines in general: EU herbal monograph section 4.5: none reported. [P6]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each dietary-ingredient component (21 CFR 111.75(a)(1)(i)) — Required by the US dietary supplement cGMP rule for any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P7]
- Harpagoside assay — Clinical evidence is tied to daily harpagoside content (e.g. extracts standardized to 50 mg or 100 mg harpagoside in low back pain trials). [P8]
- Compendial quality per Ph. Eur. monograph 1095 (devil's claw root) — The EU herbal monograph states that the herbal material complies with Ph. Eur. monograph 1095; it covers H. procumbens and/or H. zeyheri root. [P6]
Supply and conservation
- Most of the world's supply comes from Namibia, with lesser amounts from South Africa and Botswana; 1,018 metric tons of dried tubers were exported from southern Africa in the peak year 2002. [P9]
- A 2000 recommendation to add devil's claw to CITES Appendix II was formally withdrawn in 2004 after range states acted on sustainability; cultivation (including micropropagation) has been developed alongside wild collection (as reported in 2005). [P9]
Absorption in people
- In male volunteers given an oral Harpagophytum extract, plasma harpagoside peaked after 1.3 to 2.5 hours, and Cmax and AUC rose linearly with dose. [P1]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (HMPC, traditional use, EMA/HMPC/627057/2015 adopted 12 July 2016), adults and elderly, minor joint pain: e.g. 4.5 g root as infusion in 500 ml water divided into 3 doses, powdered root 1.35 g daily, or stated daily amounts for each listed extract and tincture; consult a doctor if symptoms persist longer than 4 weeks. Digestive indication: e.g. 1.5 g as infusion in 250 ml divided into 3 doses; consult a doctor if symptoms persist longer than 2 weeks. [P6]
Pregnancy and breastfeeding
- Safety during pregnancy and lactation has not been established; in the absence of sufficient data, use is not recommended (EU herbal monograph, 2016). No fertility data available. [P6]
Sources for this profile
- Loew D, et al. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 2001;69(5):356-64 (PMID 11372004), 2001-05. pubmed.ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Devil's Claw (last updated April 13, 2023), 2023-04-13. mskcc.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Agents classified by the IARC Monographs, Volumes 1–142 (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix (EMA/HMPC/627057/2015; adopted 12 July 2016), 2016-07-12. ema.europa.eu
- eCFR. 21 CFR 111.75 (Title 21 up to date as of 10/27/2026), 2026-10-27. ecfr.gov
- Oltean H, et al. Herbal medicine for low-back pain. Cochrane Database Syst Rev 2014;(12):CD004504 (PMID 25536022), 2014-12-23. pubmed.ncbi.nlm.nih.gov
- Stewart KM, Cole D. The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details. J Ethnopharmacol 2005;100(3):225-36 (PMID 16112533), 2005-09-14. pubmed.ncbi.nlm.nih.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Devil's Claw (last updated April 13, 2023), 2023-04-13. mskcc.org
- Oltean H, et al. Herbal medicine for low-back pain. Cochrane Database Syst Rev 2014;(12):CD004504 (PMID 25536022), 2014-12-23. pubmed.ncbi.nlm.nih.gov
- Gagnier JJ, et al. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004;4:13 (PMID 15369596), 2004-09-15. pubmed.ncbi.nlm.nih.gov
- Chantre P, et al. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000;7(3):177-83 (PMID 11185727), 2000-06. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix (EMA/HMPC/627057/2015; adopted 12 July 2016), 2016-07-12. ema.europa.eu
- Vlachojannis J, et al. Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain. Phytother Res 2008;22(2):149-52 (PMID 18236448), 2008-02. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Stewart KM, Cole D. The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details. J Ethnopharmacol 2005;100(3):225-36 (PMID 16112533), 2005-09-14. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Harpagophytum procumbens (Burch.) DC. (accessed 2026-10-29); distribution from WCVP, 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.